VKTX 72.28+11.89 (+19.7%)Viking Therapeutics
Outlook is neutral, with stock confined to a band of ±14%
Strategy has +85% ROI potential and 39% overvalued
VKTX Viking Therapeutics69.78+9.39 (+15.6%)
Bullish play with a target stock price of $85
Strategy has +173% upside potential and 33% undervalued
After Hours Gainer
VKTX Viking Therapeutics60.39-1.64-2.6%
After Hours:63.12+2.73 (+4.5%)
Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PRNewswireWed, 23-Oct 4:05 PM
After Hours Gainer
VKTX Viking Therapeutics60.39-1.64-2.6%
After Hours:63.05+2.66 (+4.4%)
Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PRNewswireWed, 23-Oct 4:05 PM